AVITA Medical, Inc. (RCEL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RCEL Revenue Growth
Revenue Breakdown (FY 2025)
RCEL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RCEL Revenue Analysis (2014–2025)
As of May 8, 2026, AVITA Medical, Inc. (RCEL) generated trailing twelve-month (TTM) revenue of $71.6 million, reflecting slight decline in growth of -4.3% year-over-year. The most recent quarter (Q4 2025) recorded $17.6 million in revenue, up 3.2% sequentially.
Looking at the longer-term picture, RCEL's 5-year compound annual growth rate (CAGR) stands at +19.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $71.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RCEL's business is primarily driven by Lease Revenue (100%). With over half of revenue concentrated in Lease Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including XTNT (+16.9% YoY), TELA (+12.2% YoY), and MDXG (+10.5% YoY), RCEL has underperformed the peer group in terms of revenue growth. Compare RCEL vs XTNT →
RCEL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RCELCurrent | $72M | -4.3% | +19.6% | 89.0% | |
 XTNT | $117M | +16.9% | +12.6% | -10.3% | |
 TELA | $69M | +12.2% | +35.0% | -49.2% | |
 MDXG | $419M | +10.5% | +11.0% | 15.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 APYX | $53M | +18.1% | +13.8% | -12.2% |
RCEL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $71.6M | +11.5% | $58.8M | 82.1% | $63.7M | 89.0% |
| 2024 | $64.3M | +28.1% | $55.2M | 85.8% | $-56,593,000 | -88.1% |
| 2023 | $50.1M | +45.7% | $42.4M | 84.5% | $-42,655,000 | -85.1% |
| 2022 | $34.4M | +4.2% | $28.4M | 82.4% | $-27,505,000 | -79.9% |
| 2021 | $33.0M | +13.0% | $26.9M | 81.5% | $-25,118,000 | -76.1% |
| 2020 | $29.2M | +104.9% | $23.3M | 79.6% | $-26,540,000 | -90.8% |
| 2019 | $14.3M | +160.6% | $11.3M | 79.2% | $-42,679,000 | -299.2% |
| 2018 | $5.5M | +336.1% | $4.2M | 76.8% | $-25,528,000 | -466.4% |
| 2017 | $1.3M | +6.3% | $517K | 41.2% | $-18,700,575 | -1489.9% |
| 2016 | $1.2M | +17.8% | $675K | 57.2% | $-12,670,216 | -1073.2% |
See RCEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCEL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCEL — Frequently Asked Questions
Quick answers to the most common questions about buying RCEL stock.
Is RCEL's revenue growth accelerating or slowing?
RCEL revenue growth slowed to -4.3%, below the 5-year CAGR of +19.6%. TTM revenue is $72M. The deceleration marks a shift from historical growth rates.
What is RCEL's long-term revenue growth rate?
AVITA Medical, Inc.'s 5-year revenue CAGR of +19.6% reflects the variable expansion pattern. Current YoY growth of -4.3% is near this long-term average.
How is RCEL's revenue distributed by segment?
RCEL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.